I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00335673|
Recruitment Status : Completed
First Posted : June 12, 2006
Last Update Posted : April 1, 2011
- To evaluate control rate of Blood Pressure ≤ 140/90 mm Hg in non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients.
- To determine percentage of patients achieving blood pressure control according to their profile (naïve, switch, patient history, etc…) at the end of the trial.
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: Irbesartan (Aprovel)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1630 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Irbesartan in Mild to Moderate Hypertensive Patients|
|Study Start Date :||February 2006|
|Actual Primary Completion Date :||November 2006|
|Actual Study Completion Date :||November 2006|
- Drug: Irbesartan (Aprovel)
Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
- Reduction in blood pressure to target values according to ESC 2003 guidelines at the end of the study. [ Time Frame: During the study conduct ]
- Occurrence of any side effects leading to treatment discontinuation. [ Time Frame: During the study conduct ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00335673
|Sanofi-Aventis Administrative Office|
|Study Director:||Mosaad I Morsi, MBBCh, MSc||Sanofi|